GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » KPC Pharmaceuticals Inc (SHSE:600422) » Definitions » 10-Year RORE %

KPC Pharmaceuticals (SHSE:600422) 10-Year RORE % : 5.15% (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is KPC Pharmaceuticals 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. KPC Pharmaceuticals's 10-Year RORE % for the quarter that ended in Mar. 2024 was 5.15%.

The industry rank for KPC Pharmaceuticals's 10-Year RORE % or its related term are showing as below:

SHSE:600422's 10-Year RORE % is ranked worse than
51% of 647 companies
in the Drug Manufacturers industry
Industry Median: 5.88 vs SHSE:600422: 5.15

KPC Pharmaceuticals 10-Year RORE % Historical Data

The historical data trend for KPC Pharmaceuticals's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KPC Pharmaceuticals 10-Year RORE % Chart

KPC Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.58 12.89 11.39 4.07 5.92

KPC Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.21 2.93 3.23 5.92 5.15

Competitive Comparison of KPC Pharmaceuticals's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, KPC Pharmaceuticals's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


KPC Pharmaceuticals's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, KPC Pharmaceuticals's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where KPC Pharmaceuticals's 10-Year RORE % falls into.



KPC Pharmaceuticals 10-Year RORE % Calculation

KPC Pharmaceuticals's 10-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( 0.58-0.388 )/( 5.332-1.605 )
=0.192/3.727
=5.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 10-year before.


KPC Pharmaceuticals  (SHSE:600422) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


KPC Pharmaceuticals 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of KPC Pharmaceuticals's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


KPC Pharmaceuticals (SHSE:600422) Business Description

Traded in Other Exchanges
N/A
Address
No. 166 Keyi Road, State New and High-Technology Development Zone, Kunming, Yunnan, CHN, 650106
KPC Pharmaceuticals Inc is a pharmaceutical company which focused on innovative natural botanical drugs in China. Its business scope covers traditional Chinese medicine, chemical medicine, and medicinal circulation. Its products include Panax notoginseng, gastrodine, artemether, and special botanical drugs.
Executives
Qu Xiao Ru senior management
Xie Bo senior management
Meng Li senior management
Zhong Xiang Gang senior management
Wu Sheng Long senior management
Liu Jun Feng senior management
Wang Lei senior management
Zhang Meng Xun senior management
Hu Zhen Bo senior management
Sun Lei senior management
Xu Chao Neng senior management
Wang Jun senior management
Zhao Jian senior management
He Qin Director
Dai Xiao Chang senior management

KPC Pharmaceuticals (SHSE:600422) Headlines

No Headlines